|
Video: What is a Stock Split?
|
|
XTL Biopharmaceuticals is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Co.'s existing drug, hCDR1, is a treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. hCDR1 is also Phase II-ready for the treatment of SS. SS is a chronic autoimmune disorder affecting lacrimal and salivary gland function (glandular) but may also affect other organs and systems (extraglandular) such as the kidneys, and gastrointestinal system, among others. According to our XTLB split history records, XTL Biopharmaceuticals has had 1 split. | |
|
XTL Biopharmaceuticals (XTLB) has 1 split in our XTLB split history database. The split for XTLB took place on February 10, 2017. This was a 1 for 5 reverse split, meaning for each 5 shares of XTLB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.
When a company such as XTL Biopharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the XTLB split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into XTL Biopharmaceuticals shares, starting with a $10,000 purchase of XTLB, presented on a split-history-adjusted basis factoring in the complete XTLB split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$17.15 |
|
End price/share: |
$2.56 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-85.07% |
|
Average Annual Total Return: |
-17.32% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,493.59 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
02/10/2017 | 1 for 5 |
|
|